Sporadic versus radiation-associated angiosarcoma: A comparative clinicopathologic and molecular analysis of 48 cases

Jennifer Hung, Susan M. Hiniker, David R. Lucas, Kent A. Griffith, Jonathan B. McHugh, Amichay Meirovitz, Dafydd G. Thomas, Rashmi Chugh, Joseph M. Herman

Research output: Contribution to journalArticle

Abstract

Angiosarcomas are aggressive tumors of vascular endothelial origin, occurring sporadically or in association with prior radiotherapy. We compared clinicopathologic and biologic features of sporadic angiosarcomas (SA) and radiation-associated angiosarcomas (RAA). Methods. From a University of Michigan institutional database, 37 SA and 11 RAA were identified. Tissue microarrays were stained for p53, Ki-67, and hTERT. DNA was evaluated for TP53 and ATM mutations. Results. Mean latency between radiotherapy and diagnosis of RAA was 11.9 years: 6.7 years for breast RAA versus 20.9 years for nonbreast RAA (P=0.148). Survival after diagnosis did not significantly differ between SA and RAA (P=0.590). Patients with nonbreast RAA had shorter overall survival than patients with breast RAA (P=0.03). The majority of SA (86.5%) and RAA (77.8%) were classified as high-grade sarcomas (P=0.609). RAA were more likely to have well-defined vasoformative areas (55.6% versus 27%, P=0.127). Most breast SA were parenchymal in origin (80%), while most breast RAA were cutaneous in origin (80%). TMA analysis showed p53 overexpression in 25.7% of SA and 0% RAA, high Ki-67 in 35.3% of SA and 44.4% RAA, and hTERT expression in 100% of SA and RAA. TP53 mutations were detected in 13.5% of SA and 11.1% RAA. ATM mutations were not detected in either SA or RAA. Conclusions. SA and RAA are similar in histology, immunohistochemical markers, and DNA mutation profiles and share similar prognosis. Breast RAA have a shorter latency period compared to nonbreast RAA and a significantly longer survival.

Original languageEnglish (US)
Article number798403
JournalSarcoma
Volume2013
DOIs
StatePublished - 2013

Fingerprint

Hemangiosarcoma
Radiation
Breast
Mutation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Hung, J., Hiniker, S. M., Lucas, D. R., Griffith, K. A., McHugh, J. B., Meirovitz, A., ... Herman, J. M. (2013). Sporadic versus radiation-associated angiosarcoma: A comparative clinicopathologic and molecular analysis of 48 cases. Sarcoma, 2013, [798403]. https://doi.org/10.1155/2013/798403

Sporadic versus radiation-associated angiosarcoma : A comparative clinicopathologic and molecular analysis of 48 cases. / Hung, Jennifer; Hiniker, Susan M.; Lucas, David R.; Griffith, Kent A.; McHugh, Jonathan B.; Meirovitz, Amichay; Thomas, Dafydd G.; Chugh, Rashmi; Herman, Joseph M.

In: Sarcoma, Vol. 2013, 798403, 2013.

Research output: Contribution to journalArticle

Hung, J, Hiniker, SM, Lucas, DR, Griffith, KA, McHugh, JB, Meirovitz, A, Thomas, DG, Chugh, R & Herman, JM 2013, 'Sporadic versus radiation-associated angiosarcoma: A comparative clinicopathologic and molecular analysis of 48 cases', Sarcoma, vol. 2013, 798403. https://doi.org/10.1155/2013/798403
Hung, Jennifer ; Hiniker, Susan M. ; Lucas, David R. ; Griffith, Kent A. ; McHugh, Jonathan B. ; Meirovitz, Amichay ; Thomas, Dafydd G. ; Chugh, Rashmi ; Herman, Joseph M. / Sporadic versus radiation-associated angiosarcoma : A comparative clinicopathologic and molecular analysis of 48 cases. In: Sarcoma. 2013 ; Vol. 2013.
@article{643572b0ff4d40788a6ca23d2a4fd715,
title = "Sporadic versus radiation-associated angiosarcoma: A comparative clinicopathologic and molecular analysis of 48 cases",
abstract = "Angiosarcomas are aggressive tumors of vascular endothelial origin, occurring sporadically or in association with prior radiotherapy. We compared clinicopathologic and biologic features of sporadic angiosarcomas (SA) and radiation-associated angiosarcomas (RAA). Methods. From a University of Michigan institutional database, 37 SA and 11 RAA were identified. Tissue microarrays were stained for p53, Ki-67, and hTERT. DNA was evaluated for TP53 and ATM mutations. Results. Mean latency between radiotherapy and diagnosis of RAA was 11.9 years: 6.7 years for breast RAA versus 20.9 years for nonbreast RAA (P=0.148). Survival after diagnosis did not significantly differ between SA and RAA (P=0.590). Patients with nonbreast RAA had shorter overall survival than patients with breast RAA (P=0.03). The majority of SA (86.5{\%}) and RAA (77.8{\%}) were classified as high-grade sarcomas (P=0.609). RAA were more likely to have well-defined vasoformative areas (55.6{\%} versus 27{\%}, P=0.127). Most breast SA were parenchymal in origin (80{\%}), while most breast RAA were cutaneous in origin (80{\%}). TMA analysis showed p53 overexpression in 25.7{\%} of SA and 0{\%} RAA, high Ki-67 in 35.3{\%} of SA and 44.4{\%} RAA, and hTERT expression in 100{\%} of SA and RAA. TP53 mutations were detected in 13.5{\%} of SA and 11.1{\%} RAA. ATM mutations were not detected in either SA or RAA. Conclusions. SA and RAA are similar in histology, immunohistochemical markers, and DNA mutation profiles and share similar prognosis. Breast RAA have a shorter latency period compared to nonbreast RAA and a significantly longer survival.",
author = "Jennifer Hung and Hiniker, {Susan M.} and Lucas, {David R.} and Griffith, {Kent A.} and McHugh, {Jonathan B.} and Amichay Meirovitz and Thomas, {Dafydd G.} and Rashmi Chugh and Herman, {Joseph M.}",
year = "2013",
doi = "10.1155/2013/798403",
language = "English (US)",
volume = "2013",
journal = "Sarcoma",
issn = "1357-714X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Sporadic versus radiation-associated angiosarcoma

T2 - A comparative clinicopathologic and molecular analysis of 48 cases

AU - Hung, Jennifer

AU - Hiniker, Susan M.

AU - Lucas, David R.

AU - Griffith, Kent A.

AU - McHugh, Jonathan B.

AU - Meirovitz, Amichay

AU - Thomas, Dafydd G.

AU - Chugh, Rashmi

AU - Herman, Joseph M.

PY - 2013

Y1 - 2013

N2 - Angiosarcomas are aggressive tumors of vascular endothelial origin, occurring sporadically or in association with prior radiotherapy. We compared clinicopathologic and biologic features of sporadic angiosarcomas (SA) and radiation-associated angiosarcomas (RAA). Methods. From a University of Michigan institutional database, 37 SA and 11 RAA were identified. Tissue microarrays were stained for p53, Ki-67, and hTERT. DNA was evaluated for TP53 and ATM mutations. Results. Mean latency between radiotherapy and diagnosis of RAA was 11.9 years: 6.7 years for breast RAA versus 20.9 years for nonbreast RAA (P=0.148). Survival after diagnosis did not significantly differ between SA and RAA (P=0.590). Patients with nonbreast RAA had shorter overall survival than patients with breast RAA (P=0.03). The majority of SA (86.5%) and RAA (77.8%) were classified as high-grade sarcomas (P=0.609). RAA were more likely to have well-defined vasoformative areas (55.6% versus 27%, P=0.127). Most breast SA were parenchymal in origin (80%), while most breast RAA were cutaneous in origin (80%). TMA analysis showed p53 overexpression in 25.7% of SA and 0% RAA, high Ki-67 in 35.3% of SA and 44.4% RAA, and hTERT expression in 100% of SA and RAA. TP53 mutations were detected in 13.5% of SA and 11.1% RAA. ATM mutations were not detected in either SA or RAA. Conclusions. SA and RAA are similar in histology, immunohistochemical markers, and DNA mutation profiles and share similar prognosis. Breast RAA have a shorter latency period compared to nonbreast RAA and a significantly longer survival.

AB - Angiosarcomas are aggressive tumors of vascular endothelial origin, occurring sporadically or in association with prior radiotherapy. We compared clinicopathologic and biologic features of sporadic angiosarcomas (SA) and radiation-associated angiosarcomas (RAA). Methods. From a University of Michigan institutional database, 37 SA and 11 RAA were identified. Tissue microarrays were stained for p53, Ki-67, and hTERT. DNA was evaluated for TP53 and ATM mutations. Results. Mean latency between radiotherapy and diagnosis of RAA was 11.9 years: 6.7 years for breast RAA versus 20.9 years for nonbreast RAA (P=0.148). Survival after diagnosis did not significantly differ between SA and RAA (P=0.590). Patients with nonbreast RAA had shorter overall survival than patients with breast RAA (P=0.03). The majority of SA (86.5%) and RAA (77.8%) were classified as high-grade sarcomas (P=0.609). RAA were more likely to have well-defined vasoformative areas (55.6% versus 27%, P=0.127). Most breast SA were parenchymal in origin (80%), while most breast RAA were cutaneous in origin (80%). TMA analysis showed p53 overexpression in 25.7% of SA and 0% RAA, high Ki-67 in 35.3% of SA and 44.4% RAA, and hTERT expression in 100% of SA and RAA. TP53 mutations were detected in 13.5% of SA and 11.1% RAA. ATM mutations were not detected in either SA or RAA. Conclusions. SA and RAA are similar in histology, immunohistochemical markers, and DNA mutation profiles and share similar prognosis. Breast RAA have a shorter latency period compared to nonbreast RAA and a significantly longer survival.

UR - http://www.scopus.com/inward/record.url?scp=84884879648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884879648&partnerID=8YFLogxK

U2 - 10.1155/2013/798403

DO - 10.1155/2013/798403

M3 - Article

C2 - 24082817

AN - SCOPUS:84884879648

VL - 2013

JO - Sarcoma

JF - Sarcoma

SN - 1357-714X

M1 - 798403

ER -